Literature DB >> 24776621

Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS).

Neoklis A Georgopoulos1, Efstathios Papadakis2, Anastasia K Armeni1, Ilias Katsikis2, Nikolaos D Roupas1, Dimitrios Panidis2.   

Abstract

OBJECTIVE: To evaluate the impact of elevated serum Δ4A levels on the hormonal and metabolic features of the different phenotypes of PCOS.
DESIGN: 1276 women with PCOS according to the Rotterdam criteria were included, in whom serum hormonal levels were determined.
RESULTS: In PCOS women as a whole, as well as in patients presenting clinical and/or biochemical hyperandrogenemia (phenotypes I and II), Δ4A levels >3.8 ng/ml were positively related to LH, LH/FSH ratio, T, DHEAS, 17 OH progesterone and FAI and negatively related to T/Δ4A ratio. In the milder phenotype III, a positive correlation between Δ4A levels >3.8 ng/ml and T, DHEAS, 17 OH progesterone and FAI and a negative one between increased Δ4A and T/Δ4A ratio were reported. In the whole PCOS group with androstenedione >3.8 ng/ml, an increased ovarian volume was observed, while a greater mean follicular number was found only in phenotypes I and II.
CONCLUSIONS: Increased serum Δ4A levels, which are associated with more severe PCOS phenotypes, possibly contribute to the worsening of PCOS features and therefore could be a valuable marker of biochemical hyperandrogenemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24776621     DOI: 10.1007/BF03401335

Source DB:  PubMed          Journal:  Hormones (Athens)        ISSN: 1109-3099            Impact factor:   2.885


  8 in total

Review 1.  Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome.

Authors:  Márcia Marly Winck Yamamoto; Sebastião Freitas de Medeiros
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

Review 2.  Comparison of dietary intake and physical activity between women with and without polycystic ovary syndrome: a review.

Authors:  Annie W Lin; Marla E Lujan
Journal:  Adv Nutr       Date:  2014-09       Impact factor: 8.701

3.  Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.

Authors:  Hardik Jethaliya; Nirva Gajjar; Vrushank Patel; Shrikalp Deshpande; Roshni Patel
Journal:  Reprod Sci       Date:  2022-04-27       Impact factor: 2.924

4.  Should All Women with Polycystic Ovary Syndrome Be Screened for Metabolic Parameters?: A Hospital-Based Observational Study.

Authors:  Hui Li; Lin Li; Jian Gu; Yu Li; Xiaoli Chen; Dongzi Yang
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

5.  Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene.

Authors:  Garima Sachdeva; Shalini Gainder; Vanita Suri; Naresh Sachdeva; Seema Chopra
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun

6.  Lifestyle treatment in women with polycystic ovary syndrome: predictors of weight loss and dropout.

Authors:  Geranne Jiskoot; Alexandra Dietz de Loos; Reinier Timman; Annemerle Beerthuizen; Joop Laven; Jan Busschbach
Journal:  Brain Behav       Date:  2022-06-02       Impact factor: 3.405

7.  Elevated androstenedione in young adult but not early adolescent prenatally androgenized female rats.

Authors:  Ami B Shah; Isaac Nivar; Diana L Speelman
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

8.  Plumbagin inhibits proliferation and promotes apoptosis of ovarian granulosa cells in polycystic ovary syndrome by inactivating PI3K/Akt/mTOR pathway.

Authors:  Zhaowei Cai; Shaojuan He; Tao Li; Li Zhao; Kerong Zhang
Journal:  Anim Cells Syst (Seoul)       Date:  2020-07-17       Impact factor: 1.815

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.